Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice

A systematic review

Caitlin C. Murphy, L. Kay Bartholomew, Melissa Y. Carpentier, Shirley Bluethmann, Sally W. Vernon

Research output: Contribution to journalReview article

245 Citations (Scopus)

Abstract

Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multistep process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all "maybe" abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-ofpocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population.

Original languageEnglish (US)
Pages (from-to)459-478
Number of pages20
JournalBreast Cancer Research and Treatment
Volume134
Issue number2
DOIs
StatePublished - Jul 1 2012

Fingerprint

Survivors
Breast Neoplasms
Therapeutics
Cytochrome P-450 CYP2D6
Aftercare
Aromatase Inhibitors
Tamoxifen
PubMed
General Practitioners
Referral and Consultation
Hormones
Costs and Cost Analysis
Survival
Research
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Murphy, Caitlin C. ; Bartholomew, L. Kay ; Carpentier, Melissa Y. ; Bluethmann, Shirley ; Vernon, Sally W. / Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice : A systematic review. In: Breast Cancer Research and Treatment. 2012 ; Vol. 134, No. 2. pp. 459-478.
@article{ef017edceb05467eae4f8681df42a56b,
title = "Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review",
abstract = "Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multistep process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 {\%} sample of abstracts; and (3) two sets of coauthors each reviewed half of all {"}maybe{"} abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 {\%} and discontinuation (i.e., nonpersistence) ranged from 31 to 73 {\%}, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-ofpocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population.",
author = "Murphy, {Caitlin C.} and Bartholomew, {L. Kay} and Carpentier, {Melissa Y.} and Shirley Bluethmann and Vernon, {Sally W.}",
year = "2012",
month = "7",
day = "1",
doi = "10.1007/s10549-012-2114-5",
language = "English (US)",
volume = "134",
pages = "459--478",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice : A systematic review. / Murphy, Caitlin C.; Bartholomew, L. Kay; Carpentier, Melissa Y.; Bluethmann, Shirley; Vernon, Sally W.

In: Breast Cancer Research and Treatment, Vol. 134, No. 2, 01.07.2012, p. 459-478.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice

T2 - A systematic review

AU - Murphy, Caitlin C.

AU - Bartholomew, L. Kay

AU - Carpentier, Melissa Y.

AU - Bluethmann, Shirley

AU - Vernon, Sally W.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multistep process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all "maybe" abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-ofpocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population.

AB - Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multistep process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all "maybe" abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-ofpocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population.

UR - http://www.scopus.com/inward/record.url?scp=84868204335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868204335&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-2114-5

DO - 10.1007/s10549-012-2114-5

M3 - Review article

VL - 134

SP - 459

EP - 478

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -